TSC2 and cancer: In posttherapy HPD tumors, several somatic mutations were observed in known cancer genes that include tumor suppressor genes such as TSC2 and VHL, along with transcriptional upregulation of cancer signaling pathways, which include IGF-1, ERK/MAPK, and PI3K/AKT (3).